Table S5.

Number (%) of patients with most common adverse events (AEs) (frequency of ≥2% in any treatment group) in the 3-month budesonide/formoterol vs placebo pool (Welte et al, Calverley et al, and Szafranski et al studies)^1,2,4

Preferred term	Budesonide/formoterol (n=791)	Placebo (n=791)
Chronic obstructive pulmonary disease	56 (7.1%)	103 (13.0%)
Nasopharyngitis	30 (3.8%)	26 (3.3%)
Headache	12 (1.5%)	7 (0.9%)
Dysphonia	14 (1.8%)	0 (0.0%)
Pharyngitis	4 (0.5%)	7 (0.9%)
Pyrexia	9 (1.1%)	1 (0.1%)

Notes: This table includes patients with AEs onset during randomized treatment. Patients with multiple AEs coded to the same preferred term are counted only once for that preferred term.